CEP63

Across TCGA pan-cancer cohorts, CEP63 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated CEP63 data layer compared with 6 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher CEP63 RNA is associated with better overall survival. In most high-consensus cancer types, elevated CEP63 expression acts as an unfavorable survival marker, although some lineages such as UCS and SKCM show a favorable association.

UCS, ACC, and LIHC are the cancer types where CEP63 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Quartile	II,III,IV	0.695	0.332	.004	64	view →
ACC	DFS	Median	All	0.235	0.628	<.001	50	view →
LIHC	OS	Quartile	All	0.679	0.861	<.001	30	view →
KICH	DFS	Median	II,III,IV	0.575	0.922	.006	29	view →
LUSC	DFS	Median	III,IV	0.471	0.923	.002	28	view →
SKCM	DFS	Quartile	All	0.278	0.112	<.001	25	view →
CHOL	DFS	Median	All	0.632	0.189	.010	22	view →
LGG	OS	Median	All	0.728	0.942	<.001	17	view →
BLCA	OS	Quartile	All	0.465	0.733	.028	12	view →
THCA	DFS	Tertile	All	0.980	0.918	.008	12	view →
MESO	DFS	Tertile	All	0.278	0.706	.019	12	view →
HNSC	OS	Tertile	All	0.284	0.542	.006	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

CEP63–UCS (OS)

Open the UCS breakdown →